Here, we used the LRP-1 agonistic peptide, SP16, during advanced NAFLD to determine whether inhibiting CD4+ T cell apoptosis and modulation of inflammation could prevent HCC [7]. Here, CD4 is linked to metabolic dysfunction-associated steatotic liver disease.